ConductScience.org, home

Comparison · NCT02612337-21624d7e

OTO-104 (Safety Analysis Set) vs Placebo (Safety Analysis Set): Otoscopic Examination - Tympanic Membrane Perforation at Week 12 (Month 3)

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. OTO-104 (Safety Analysis Set) vs Placebo (Safety Analysis Set): Otoscopic Examination - Tympanic Membrane Perforation at Week 12 (Month 3). Trial comparisons, record NCT02612337-21624d7e. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02612337-21624d7e

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.04880.01910.119wilson
Risk in group 200.000000000000000003470.0442wilson
Risk difference, group 1 minus group 20.0488-0.004470.119newcombe hybrid score
Risk ratio, group 1 over group 2loga group has no participants with the outcome
Odds ratio, group 1 over group 2loga cell of the two-by-two table is zero
Number needed to treat, for one more participant with the outcome on OTO-104 (Safety Analysis Set) than on Placebo (Safety Analysis Set)20.5from the risk difference intervalthe interval includes no difference

Groups2

Group 2 names the comparator: placebo.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1OTO-104 (Safety Analysis Set)All subjects who received OTO-104. Subjects were included in this treatment group according to the actual treatment received regardless of their randomized assignment.482OG000
Group 2Placebo (Safety Analysis Set)All subjects who received Placebo. Subjects were included in this treatment group according to the actual treatment received regardless of their randomized assignment.083OG001

Outcome

Type
SECONDARY
Title
Otoscopic Examination - Tympanic Membrane Perforation at Week 12 (Month 3)
Description
Otoscopic examinations were conducted at each visit. It was considered important to understand if the tympanic perforation that resulted from the IT injection at the Baseline visit persisted at the end of study visit (Week 12 \[Month 3\]).
Time frame
3 months
Population

Source ClinicalTrials.gov

Trial

Title
Study of OTO-104 in Subjects With Unilateral Meniere's Disease
NCT number
NCT02612337
Phases
PHASE3
Conditions
Meniere's Disease
Interventions
OTO-104, Placebo
Lead sponsor
Otonomy, Inc.
Results first posted
2023-01-12

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT02612337-21624d7e